Aptima Combo 2 (AC2) Neisseria gonorrhoeae testing of 81,405 patients who were tested by culture and 14,666 who were AC2 tested for Chlamydia trachomatis detected 142 extra infections and confirmed 106 culture-positive samples (the positivity rate increased from 0.13 in testing by culture to 0.26 in testing by AC2). Retrievable AC2 positive samples were confirmed (98.5%) by an alternate AGC test.Lower genital tract infections with Neisseria gonorrhoeae may be asymptomatic and accompanied by Chlamydia trachomatis infection(13). Efforts are needed to identify and treat lower tract infections to prevent upper tract complications, such as pelvic inflammatory disease, ectopic pregnancy, or tubal infertility in women and less commonly epididymitis or prostatitis in men, as well as transmission between asymptomatically infected patients and their uninfected partners. Attempts to culture N. gonorrhoeae from clinical specimens can be unsuccessful. Testing for N. gonorrhoeae with nucleic acid amplification tests (NAATs) has increased diagnostic sensitivity (3,4,9,11,18,19) using traditional and less-invasive sampling. Although not all are FDA cleared, first-void urine (FVU), self-collected vaginal swabs (VS), and anal and oral swabs have been shown to yield positive results (1,7,15). The commercially available transcription-mediated amplification (TMA) test Aptima Combo 2 (AC2) is able to detect N. gonorrhoeae and C. trachomatis RNA in clinical specimens collected in specimen transportation media (STM), with no crossreactions with non-N. gonorrhoeae strains. Positives can be confirmed in alternate individual TMA tests, Aptima GC (AGC) (for N. gonorrhoeae) and APTIMA CT (ACT) (for C. trachomatis) (2, 12).Community physicians practicing in Southern Ontario who suspect that their patient may have an N. gonorrhoeae infection traditionally submit cervical swabs (CS) from women and urethral swabs (US) from men for culture. If a C. trachomatis infection is suspected, an NAAT will be ordered for a CS or FVU. If both infections are suspected, specimens are collected for N. gonorrhoeae culture and C. trachomatis nucleic acid amplification testing. We evaluated the utility of performing additional AC2 testing for N. gonorrhoeae on specimens submitted for N. gonorrhoeae culture and C. trachomatis TMA. The objectives were as follows: (i) to perform N. gonorrhoeae testing by AC2 on STM samples from patients receiving N. gonorrhoeae culture, (ii) to test STM samples submitted for C. trachomatis testing for N. gonorrhoeae, and (iii) to confirm AC2-GC positives using the AGC assay.From March to August 2008, the microbiology laboratory at Gamma Dynacare Medical Laboratories in Brampton, Canada, received 96,071 urogenital samples from 961 men (FVU or US) and 95,110 women (FVU or CS) for C. trachomatis and N. gonorrhoeae testing or C. trachomatis testing only (Fig. 1). There were 81,405 patients in group A, whose physicians submitted a swab collected in an M40 Transystem specimen transport system (Copan Diagnostics Inc.) for N. gonorrhoeae c...